<?xml version="1.0" encoding="UTF-8"?>
<results title="drugs">
 <result pre="been approved for use in infectious disease settings, such as" exact="palivizumab" post="for respiratory syncytial virus and ibalizumab-uiyk for the treatment"/>
 <result pre="indications that may benefit from mAb combination therapy (such as" exact="trastuzumab" post="with pertuzumab for HER2+ breast cancer), is the relative"/>
 <result pre="may benefit from mAb combination therapy (such as trastuzumab with" exact="pertuzumab" post="for HER2+ breast cancer), is the relative ease of"/>
 <result pre="doi:10.1002/jmv.25897 doi: 10.1016/j.jinf.2020.03.037 75GiambenedettoSD, CicculloA, BorghettiA, et al.Off-label Use of" exact="tocilizumab" post="in patients with SARS-CoV-2 infection. J Med Virol. 2020."/>
 <result pre="2020. doi:10.1002/jmv.25897. 76CavalliG, LucaGD, CampochiaroC, et al.Interleukin-1 blockade with high-dose" exact="anakinra" post="in patients with COVID-19, acute respiratory distress syndrome, and"/>
</results>
